[go: up one dir, main page]

CL2007002421A1 - Composicion farmaceutica que comprende {1s-[1alfa,2alfa,3beta (1s*, 2r*),5beta]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3h-1,2,3-triazolo[4,5-d]pirimidin-3-l)-5-(2-hidroxietoxi)ciclopentano-1,2-diol, una o mas cargas, aglutinant - Google Patents

Composicion farmaceutica que comprende {1s-[1alfa,2alfa,3beta (1s*, 2r*),5beta]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3h-1,2,3-triazolo[4,5-d]pirimidin-3-l)-5-(2-hidroxietoxi)ciclopentano-1,2-diol, una o mas cargas, aglutinant

Info

Publication number
CL2007002421A1
CL2007002421A1 CL200702421A CL2007002421A CL2007002421A1 CL 2007002421 A1 CL2007002421 A1 CL 2007002421A1 CL 200702421 A CL200702421 A CL 200702421A CL 2007002421 A CL2007002421 A CL 2007002421A CL 2007002421 A1 CL2007002421 A1 CL 2007002421A1
Authority
CL
Chile
Prior art keywords
propiltio
hydroxyetoxi
aglutinant
2alfa
cyclopropil
Prior art date
Application number
CL200702421A
Other languages
English (en)
Inventor
Simon Banks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39107049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2007002421A1 publication Critical patent/CL2007002421A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL200702421A 2006-08-21 2007-08-20 Composicion farmaceutica que comprende {1s-[1alfa,2alfa,3beta (1s*, 2r*),5beta]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3h-1,2,3-triazolo[4,5-d]pirimidin-3-l)-5-(2-hidroxietoxi)ciclopentano-1,2-diol, una o mas cargas, aglutinant CL2007002421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82308306P 2006-08-21 2006-08-21

Publications (1)

Publication Number Publication Date
CL2007002421A1 true CL2007002421A1 (es) 2008-04-04

Family

ID=39107049

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702421A CL2007002421A1 (es) 2006-08-21 2007-08-20 Composicion farmaceutica que comprende {1s-[1alfa,2alfa,3beta (1s*, 2r*),5beta]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3h-1,2,3-triazolo[4,5-d]pirimidin-3-l)-5-(2-hidroxietoxi)ciclopentano-1,2-diol, una o mas cargas, aglutinant

Country Status (35)

Country Link
US (2) US8425934B2 (es)
EP (1) EP2056832B1 (es)
JP (2) JP5385139B2 (es)
KR (1) KR101539467B1 (es)
CN (1) CN101505754A (es)
AR (1) AR062451A1 (es)
AU (2) AU2007288541B9 (es)
BR (1) BRPI0715712B8 (es)
CA (1) CA2659328C (es)
CL (1) CL2007002421A1 (es)
CO (1) CO6150163A2 (es)
CY (1) CY1119380T1 (es)
DK (1) DK2056832T3 (es)
ES (1) ES2625930T3 (es)
HR (1) HRP20170694T1 (es)
HU (1) HUE031939T2 (es)
IL (2) IL196700A (es)
LT (1) LT2056832T (es)
MX (1) MX340403B (es)
MY (2) MY175009A (es)
NO (1) NO341787B1 (es)
NZ (2) NZ574514A (es)
PH (1) PH12013501627A1 (es)
PL (1) PL2056832T3 (es)
PT (1) PT2056832T (es)
RS (1) RS55884B1 (es)
RU (2) RU2476223C2 (es)
SA (1) SA07280442B1 (es)
SG (1) SG177162A1 (es)
SI (1) SI2056832T1 (es)
TW (1) TWI482772B (es)
UA (1) UA99105C2 (es)
UY (1) UY30551A1 (es)
WO (1) WO2008024045A1 (es)
ZA (1) ZA200900991B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CN101208316B (zh) 2005-08-15 2012-05-09 贝林格尔·英格海姆国际有限公司 制备β-模拟物的方法
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
US20160120869A1 (en) 2013-05-29 2016-05-05 Ratiopharm Gmbh Solid pharmaceutical dosage form
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104644604A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 替格瑞洛倍半水合物胶囊及其制备方法
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
CN104098520B (zh) * 2014-07-23 2016-01-20 张远强 苯基三唑希夫碱类化合物、其制备方法和用途
KR20160012706A (ko) * 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
EP3730142A1 (en) * 2015-01-27 2020-10-28 Astrazeneca Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CN105709230B (zh) * 2016-03-01 2019-05-31 北京鑫兰医药科技有限公司 一种替格瑞洛药物组合物及其制备方法
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107595789B (zh) 2016-04-21 2021-01-15 阿斯利康(瑞典)有限公司 口腔崩解片
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
TR201617983A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
EP3761965A1 (en) 2018-03-08 2021-01-13 Pharmaceutical Oriented Services Ltd Ticagrelor-containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
JP7657041B2 (ja) 2020-08-19 2025-04-04 アストラゼネカ・アクチエボラーグ 併用療法
US20240285636A1 (en) * 2021-06-14 2024-08-29 Libbs Farmacêutica Ltda Pharmaceutical composition and use of the pharmaceutical composition
CN120129530A (zh) 2022-10-28 2025-06-10 阿斯利康(瑞典)有限公司 以40mg至240mg的剂量用于在治疗缺血事件中使用的重组腺苷三磷酸双磷酸酶蛋白

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
AU2003218058A1 (en) 2002-02-15 2003-09-04 Teva Gyogyszergyar Reszvenytarsasag Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
WO2006085838A1 (en) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
EP1558218A1 (en) 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004037263A1 (en) 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Pharmaceutical compositions of ganciclovir
SE0203778D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
JP2005538038A (ja) * 2003-02-19 2005-12-15 テバ ジョジセルジャール レースベニュタールシャシャーグ 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
KR20070026577A (ko) 2004-05-13 2007-03-08 베링거 인겔하임 인터내셔날 게엠베하 혈소판 억제제 저항성 치료를 위한 디피리다몰의 용도
WO2006072878A1 (en) 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
AU2007288541A1 (en) 2008-02-28
US8425934B2 (en) 2013-04-23
SA07280442B1 (ar) 2012-04-07
RU2009104330A (ru) 2010-09-27
EP2056832A1 (en) 2009-05-13
NO20090425L (no) 2009-03-05
JP2010501554A (ja) 2010-01-21
PL2056832T3 (pl) 2017-09-29
MX340403B (es) 2016-07-07
WO2008024045A1 (en) 2008-02-28
AU2011205164B2 (en) 2014-02-06
CA2659328A1 (en) 2008-02-28
DK2056832T3 (en) 2017-05-22
IL229130A0 (en) 2013-12-31
MY175009A (en) 2020-06-02
CO6150163A2 (es) 2010-04-20
UY30551A1 (es) 2008-03-31
TW200817412A (en) 2008-04-16
BRPI0715712B1 (pt) 2021-03-23
RS55884B1 (sr) 2017-08-31
HRP20170694T1 (hr) 2017-07-28
RU2012153069A (ru) 2014-06-10
AR062451A1 (es) 2008-11-12
AU2007288541B9 (en) 2011-10-06
NZ596700A (en) 2013-05-31
IL196700A (en) 2014-08-31
SI2056832T1 (sl) 2017-07-31
MX2009001853A (es) 2009-03-02
CN101505754A (zh) 2009-08-12
LT2056832T (lt) 2017-05-25
TWI482772B (zh) 2015-05-01
BRPI0715712A2 (pt) 2014-06-24
ES2625930T3 (es) 2017-07-21
CY1119380T1 (el) 2018-02-14
AU2007288541B2 (en) 2011-08-25
ZA200900991B (en) 2010-02-24
CA2659328C (en) 2015-08-11
SG177162A1 (en) 2012-01-30
EP2056832B1 (en) 2017-03-22
MY147966A (en) 2013-02-28
UA99105C2 (ru) 2012-07-25
JP2014040448A (ja) 2014-03-06
NO341787B1 (no) 2018-01-22
IL196700A0 (en) 2009-11-18
PH12013501627A1 (en) 2014-11-10
HUE031939T2 (en) 2017-08-28
AU2011205164A1 (en) 2011-08-25
KR101539467B1 (ko) 2015-07-24
BRPI0715712B8 (pt) 2021-05-25
US20130131087A1 (en) 2013-05-23
PT2056832T (pt) 2017-05-22
NZ574514A (en) 2012-01-12
JP5385139B2 (ja) 2014-01-08
EP2056832A4 (en) 2012-12-26
US20080058353A1 (en) 2008-03-06
KR20090055561A (ko) 2009-06-02
RU2476223C2 (ru) 2013-02-27

Similar Documents

Publication Publication Date Title
CL2007002421A1 (es) Composicion farmaceutica que comprende {1s-[1alfa,2alfa,3beta (1s*, 2r*),5beta]}-3-(7-{[2-(3,4-difluorofenil)ciclopropil]amino}-5-(propiltio)-3h-1,2,3-triazolo[4,5-d]pirimidin-3-l)-5-(2-hidroxietoxi)ciclopentano-1,2-diol, una o mas cargas, aglutinant
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
CL2004000306A1 (es) Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
SMAP200800041A (it) Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
EP1924253A4 (en) CYCLIC NITRA COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR APPLICATIONS
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2007001597A1 (es) Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
CL2004001921A1 (es) Compuestos derivados de pirimidina; composicion que los cintoene utiles como insecticidas y antihelminticos.
BRPI0614413A2 (pt) composto, e, composição farmacêutica